Researchers at the University of British Columbia and BC Cancer have identified inherited cyclin-dependent kinase 12 (CDK12) mutations as a rare driver of aggressive hereditary prostate cancer. This discovery, published in Cancer Discovery, suggests that screening family members of carriers could allow for early intervention in high-risk patients, shifting the clinical approach from reactive to preventative.
Genomic Screening for Hereditary Prostate Cancer
Until recently, medical consensus held that CDK12 mutations in prostate cancer were strictly somatic, meaning they occurred spontaneously within tumor cells rather than being passed down. The study, led by senior author Alexander Wyatt and lead author Sofie Tolmeijer, contradicts this by identifying five unrelated men with inherited variants. These patients developed metastatic disease between the ages of 44 and 62.
The mutation prevalence sits at roughly one in every 1,000 cases of aggressive prostate cancer. Because these variants are hereditary, they can be traced through family lines. Researchers noted a potential link to ovarian cancer, as several patients in the study reported a family history of the disease. Integrating CDK12 testing into standard hereditary cancer panels could be a straightforward clinical upgrade, as existing sequencing technology is already capable of detecting these mutations.
Inherited CDK12 mutations were previously thought to arise only spontaneously within tumor cells in prostate cancer. Identifying them now allows clinicians to screen relatives before cancer develops, potentially saving lives through early detection.
The Evolving Landscape of ATTR-CM Treatment
The field of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) faces a new reality: as the standard of care improves, the bar for demonstrating additive clinical benefit rises. Ionis Pharmaceuticals and AstraZeneca recently announced that their Phase 3 CARDIO-TTRansform trial—the largest ever conducted for the condition—failed to meet its primary endpoint.
The drug, eplontersen, is an RNA-targeted silencer designed to reduce TTR protein production in the liver. However, 57 percent of the 1,432 enrolled patients were already taking TTR stabilizers at the start of the study, and another 24 percent began taking them during the trial. Subgroup analysis suggested that while eplontersen may be effective as a monotherapy, its impact is masked when used alongside existing stabilizers. Full data will be presented at the European Society of Cardiology Congress in August 2026.
Clinical Developments in Duchenne Muscular Dystrophy
Satellos recently released six-month interim data for its oral small molecule drug, SAT-3247, aimed at treating Duchenne muscular dystrophy (DMD). The study, which included four adults aged 21–28, showed reduced muscle fat fraction and stable strength levels.
The drug functions by inhibiting AAK1, which restores the division capacity of muscle stem cells. According to Perry Shieh, Professor of Neurology and Pediatrics at the David Geffen School of Medicine at UCLA, the consistency across strength, muscle composition, and safety metrics is encouraging. If successful, this oral treatment could provide an alternative to existing gene therapies.
Regulatory Scrutiny and Market Shifts
The FDA’s Office of Prescription Drug Promotion is increasing its oversight of pharmaceutical marketing. In a recent untitled letter, the agency warned Lundbeck that specific webpages for its migraine drug, Vyepti, were “false or misleading.” The FDA flagged claims that 40 percent of patients were 100 percent migraine-free, noting that these figures relied on exploratory post hoc analyses rather than primary trial outcomes.
Meanwhile, the market for pattern hair loss is seeing significant movement. Veradermics has seen its shares rise more than 650 percent since its February debut. Its lead candidate, VDPHL01, is an oral minoxidil formulation. If approved, it would be the first FDA-approved oral treatment for pattern hair loss in nearly 30 years and the first oral therapy specifically approved for female pattern hair loss. The company is positioning itself to compete in a global market projected to reach $30 billion by 2028.
Frequently Asked Questions
Can CDK12 mutations be passed down to children?
Yes. Researchers at the University of British Columbia and BC Cancer have confirmed that CDK12 mutations can be inherited, meaning they can be passed through family lines.
Why did the Ionis and AstraZeneca heart drug trial fail its primary endpoint?
The trial did not show a statistically significant reduction in cardiovascular events compared to placebo. Researchers believe this is because a large majority of the participants were already taking other TTR stabilizers, which made it difficult to measure the additional benefit of eplontersen.
What is the status of the oral hair loss drug from Veradermics?
The drug, VDPHL01, has shown statistically significant hair growth in Phase 2/3 trials. The company expects topline data from a confirmatory Phase 3 study later this year.
Stay informed on the latest biotech breakthroughs. Subscribe to our newsletter for weekly updates on clinical trials, FDA decisions, and emerging medical research.
